Xeomin® – IncobotulinumtoxinA [Korean Edition,Merz Pharmaceuticals]

 – IncobotulinumtoxinA [Korean Edition] | Naked Botulinum Toxin for Export Use

Product Overview

Xeomin® is a high-purity botulinum toxin Type A (IncobotulinumtoxinA) developed by Merz Pharmaceuticals (Germany) and globally recognized for its unique “naked” toxin formulation—free from complexing proteins. The Korean Edition of Xeomin® is manufactured under license or distributed through authorized Korean pharmaceutical channels, intended exclusively for international export use.

With no accessory proteins, Xeomin® significantly reduces the risk of antibody formation, making it one of the most stable and immunologically clean botulinum formulations available. This edition is not registered for use in the South Korean domestic market and is supplied only for export to licensed buyers for non-clinical evaluation, market testing, or institutional review.

---

Key Features & Advantages

• ✅ Made under Merz Global Standards
  Produced in accordance with European GMP protocols, ensuring pharmaceutical-grade consistency.

• ✅ Naked Neurotoxin (No Complexing Proteins)
  Reduces antigenic load, lowers the risk of immunogenic response with repeated exposure.

• ✅ High Molecular Precision
  Supports advanced research in pure neurotoxin behavior and signal modulation.

• ✅ Stable, Room-Temperature Formulation
  Excellent shelf stability and storage logistics for global shipping.

• ✅ Export-Only Korean Edition
  Intended for international scientific, research, or market-entry evaluation purposes.

---

Product Specifications

• Product Name: Xeomin® – IncobotulinumtoxinA

• Formulation: Naked botulinum toxin type A (free from complexing proteins)

• Strength: 100 Units / vial

• Form: Lyophilized powder

• Appearance: White powder; forms a clear, colorless solution upon reconstitution

• Origin: Manufactured or distributed under Korean licensing (Merz)

• Storage Conditions: Stable at 2°C–8°C; reconstituted product should be used within 24 hours

• Use Classification: Export Use Only – Not approved for clinical or cosmetic use in Korea

---

Mechanism of Action

Xeomin® acts by inhibiting the release of acetylcholine at the neuromuscular junction, similar to other botulinum toxins. Its active neurotoxin binds to presynaptic cholinergic neurons, enters the cell, and cleaves SNAP-25, a critical protein for synaptic vesicle fusion and neurotransmitter release.

What distinguishes Xeomin® is its lack of complexing proteins, which allows for pure toxin function with reduced immunogenicity. This makes it particularly valuable in long-term modeling, immune response studies, and comparative toxin research.

Further scientific details: NIH Mechanism Review

---

Use Cases in Export Markets

• Comparative studies with Botox®, Dysport®, Nabota®, etc.

• Academic and institutional toxin analysis

• Pre-market sampling by licensed distributors

• Immune-response modeling to botulinum formulations

• Research on pure neurotoxin pharmacodynamics

---

Compliance Statement

This product is manufactured or distributed under Merz licensing as the Korean Edition of Xeomin®, designated exclusively for export. It is not approved for use in clinical, therapeutic, or cosmetic procedures within South Korea and must not be used for human or animal injection. All importers and users are responsible for regulatory compliance in their country of destination.

---

Tags / Keywords

Xeomin Korean Edition, IncobotulinumtoxinA, Naked Botulinum Toxin, Merz Botulinum, Export-Only Botulinum, SNAP-25 Cleavage, Botulinum Toxin for Research, Toxin Without Complexing Proteins, Immunogenicity-Free Botulinum, Non-Clinical Neurotoxin

---

External References

• Official Xeomin® Website (Merz)

• NIH Review – Botulinum Toxin Mechanism of Action

• FDA Label for Xeomin®